Assessment of the correct use of low-molecular-weight heparins (LMWHs) in patients with indication for anticoagulant therapy taking into account adjustment to body weight, age, and creatinine clearance

Evaluación del uso correcto de las heparinas de bajo peso molecular (HBPM) en pacientes con indicación de anticoagulación, evaluando el ajuste según peso, edad y depuración de creatinina

Objectives: the proper application of the guidelines for anticoagulation and adjustment according to weight, age and creatinine clearance in adult patients hospitalized in HUSI.

Methodology: descriptive study in which 629 were reviewed records of patients hospitalized at the Hospital Universitario de san ignacio during the period between 2009 and 2010, received individual lMWH as directed. they were divided into groups according to the drug received nadroparin the first group was of 0.6 with 10 patients (group 1), nadroparin 0.3 with 18 patients (group 2), dalteparin 2500 with 183 patients (group 3), enoxaparin 80 mg with 418 patients (group 4).

Results: adjusted only 17% against 83% of patients who should have adjusted the causes were weight, followed by renal function, and major surgery. in group 2 did not meet the 17% against 83% of which should have been adjusted mainly by weight, followed by major surgery, renal function, age and cancer. in group 3 was adjusted to 14% against 86% were due to be adjusted for cancer, followed by creatinine clearance, major surgery, age and finally by weight. In group 4 were adjusted to 43% against 57% were due primarily to adjust for major surgery, followed by creatinine clearance, oncology, followed by age and weight.

Conclusions: it must take into account the variables described for adjusting the dose of lMWH in hospitalized patients because it increases the risk of thrombo-embolic venous disease.